The Changing Epidemiology of Hepatocellular Carcinoma :  Experience of a Single Center

Abstract

Aims. To analyze the main etiological factors and some clinical features of patients with hepatocellular carcinoma (HCC) at diagnosis and to compare them with those we described ten years ago. Materials and Methods. We compared two groups of patients with HCC, Group 1 consisting of 132 patients (82 M, 50 F) diagnosed in the 2003-2008 period and Group 2 including 119 patients (82 M, 37 F) diagnosed in the 2013-2018 period. For all patients, age, sex, viral markers, alcohol consumption, serum alpha-fetoprotein (AFP) levels, and the main liver function parameters were recorded. e diagnosis of HCC was based on AASLD, EASL guidelines. e staging was classified according to the "Barcelona Clinic Liver Cancer staging system" (BCLC). Results. Mean age was 69.0 ± 8 years in Group 1 and 71.0 ± 9 in Group 2 (P < 0.05). HCV subjects were significantly older in Group 2 (P < 0.05), and there was no difference for those with other etiologies. e main etiology in the two groups was HCV 80% (Group 1) versus 73% (Group 2) (P � ns), and there was no difference for HBV. Nonviral etiology was higher in Group 2 versus Group 1 (17% versus 9%; P < 0.05). e Child class at diagnosis showed no difference between the two groups, whereas in Group 2 the HCC staging according to BCLC was less severe (P < 0.02). When comparing the viral versus post-NASH BCLC in patients of the second period alone, the staging was more severe in the latter (P < 0.01). AFP serum levels were normal in 37% of cases in Group 1 and in 67% in Group 2 (P < 0.0001) and were less frequently diagnostic in post-NASH than in other etiologies (P < 0.03).Conclusions. is study shows that over the last decade a number of features of patients with HCC in our region have changed, particularly age at onset, etiological factors, and staging of HCC.

Galectin-3 is not useful for hepatocellular carcinoma surveillance in cirrhotic patients but it may be a marker of cirrhosis development

“…Hepatocellular carcinoma is usually asymptomatic [5]. Most HCC patients present with non-operable disease, and so early diagnosis is important to achieve a better prognosis [3,5].…”

“…Liver cirrhosis is the main etiology for HCC [3]. Early detection of HCC is important to achieve better management outcomes [4].…”

Cogent role of flavonoids as key orchestrators of chemoprevention of hepatocellular carcinoma: A review

“…Hepatocellular carcinoma affects more than 500,000 people every year globally with a 5‐year mortality rate of 95% or above and the death from liver cancer is projected to rise more than one million by 2030 (McGlynn & London, 2011; Tang et al, 2018). The disease usually develops in the context of chronic inflammation and present as an end or advanced‐stage cancer which is evolved through various neoplastic transformations such as fatty liver, fibrosis, and cirrhosis, thus associated with poor prognosis and survival (Calzadilla Bertot & Adams, 2016; Giannitrrapani et al, 2020; Singal et al, 2020). The complex genetic‐pathological phenotype and delayed diagnosis limits surgical‐radio therapy options and hurdled even the most advanced systemic therapies with limited tumor response and survival benefits, as most of the patients fail to complete the therapy due to dosage regimen‐associated adverse effect (Schlachterman, 2015) Table 1.…”

An Insight into the Novel Immunotherapy and Targeted Therapeutic Strategies for Hepatocellular Carcinoma and Cholangiocarcinoma

“…Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) constitute highly malignant forms of primary liver cancers, with the former being the third most frequent cause of death, due to cancer and the main cause of morbidity in cirrhotic patients [ 1 ]. The latter represents a rare form of gastrointestinal cancer (3%), associated with increased morbidity, which is attributed to the delayed time of diagnosis when the disease is already advanced [ 2 ].…”